Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.01 USD
+0.01 (0.90%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $1.00 -0.01 (-0.50%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Iterum Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 61 | 81 | 15 | 5 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 2 | 7 | 7 |
Total Current Assets | 26 | 62 | 83 | 21 | 12 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 2 | 3 | 0 | 0 |
Deposits & Other Assets | 1 | 3 | 5 | 11 | 13 |
Total Assets | 26 | 67 | 92 | 33 | 26 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 1 | 1 | 15 |
Current Portion Long-Term Debt | 0 | 0 | 2 | 6 | 6 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 4 | 1 | 2 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 9 | 33 | 3 |
Total Current Liabilities | 14 | 9 | 13 | 42 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 11 | 10 | 7 | 22 | 8 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 20 | 21 | 19 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 33 | 39 | 41 | 83 | 52 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 2 | 0 | 0 |
Capital Surplus | 455 | 451 | 427 | 236 | 209 |
Retained Earnings | -461 | -423 | -378 | -287 | -235 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -6 | 28 | 50 | -51 | -26 |
Total Liabilities & Shareholder's Equity | 26 | 67 | 92 | 33 | 26 |
Total Common Equity | -6 | 28 | 50 | -51 | -26 |
Shares Outstanding | 13.40 | 12.20 | 12.10 | 3.20 | 0.90 |
Book Value Per Share | -0.48 | 2.30 | 4.15 | -15.80 | -29.16 |
Fiscal Year End for Iterum Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 12 | 18 | 24 | 36 | 45 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 2 | 3 | 3 |
Total Current Assets | 14 | 19 | 26 | 39 | 48 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 1 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 2 |
Total Assets | 14 | 20 | 26 | 40 | 51 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 5 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 12 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 8 | 9 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 14 | 1 | 1 | 2 | 2 |
Total Current Liabilities | 17 | 18 | 14 | 16 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 11 | 12 | 12 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 8 | 7 | 21 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 26 | 33 | 36 | 44 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 462 | 462 | 455 | 452 | 452 |
Retained Earnings | -473 | -468 | -461 | -449 | -445 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -11 | -6 | -6 | 3 | 7 |
Total Liabilities & Shareholder's Equity | 14 | 20 | 26 | 40 | 51 |
Total Common Equity | -11 | -6 | -6 | 3 | 7 |
Shares Outstanding | 16.50 | 16.50 | 13.40 | 13.00 | 12.90 |
Book Value Per Share | -0.66 | -0.37 | -0.48 | 0.26 | 0.55 |